Department of Biochemistry and Nutrition, Central Food Technological Research Institute (CFTRI), Council of Scientific and Industrial Research (CSIR), Mysore, Karnataka, India.
Can J Physiol Pharmacol. 2012 Apr;90(4):387-94. doi: 10.1139/y11-135. Epub 2012 Mar 16.
Osmotic and oxidative stress have been implicated in the pathogenesis of diabetic cataract. Nigerloxin, a fungal metabolite, has been shown to possess aldose reductase inhibitory and free radical scavenging potential, in vitro. In the present study, the beneficial influence of nigerloxin was investigated on diabetes-induced alteration in the eye lens of rats treated with streptozotocin. Groups of diabetic rats were administered nigerloxin orally (100 mg·(kg body mass)(-1)·day(-1)) for 30 days. The activity of lens polyol pathway enzymes (aldose reductase and sorbitol dehydrogenase), lipid peroxides, and advanced glycation end products (AGEs) were increased in the diabetic animals. Levels of glutathione as well as the activity of antioxidant enzymes (superoxide dismutase, glutathione-S-transferase, and glutathione peroxidase) were decreased in the eye lens of the diabetic animals. The administration of nigerloxin significantly decreased levels of lipid peroxides and AGEs in the lens of the diabetic rats. Increase in the activity of aldose reductase and sorbitol dehydrogenase in the lens was countered by nigerloxin treatment. The activity of glutathione and antioxidant enzyme in the lens was significantly elevated in nigerloxin-treated diabetic rats. Examination of the treated rats' eyes indicated that nigerloxin delayed cataractogenesis in the diabetic rats. The results suggest the beneficial countering of polyol pathway enzymes and potentiation of the antioxidant defense system by nigerloxin in diabetic animals, implicating its potential in ameliorating cataracts in diabetics.
渗透和氧化应激与糖尿病性白内障的发病机制有关。 Nigerloxin 是一种真菌代谢产物,已被证明具有醛糖还原酶抑制和自由基清除潜力,在体外。在本研究中,研究了 Nigerloxin 对链脲佐菌素治疗的糖尿病大鼠眼晶状体改变的有益影响。糖尿病大鼠组经口给予 Nigerloxin(100mg·(kg 体重)(-1)·天(-1))30 天。糖尿病动物晶状体多元醇途径酶(醛糖还原酶和山梨醇脱氢酶)、脂质过氧化物和晚期糖基化终产物(AGEs)的活性增加。糖尿病动物晶状体中谷胱甘肽水平以及抗氧化酶(超氧化物歧化酶、谷胱甘肽-S-转移酶和谷胱甘肽过氧化物酶)的活性降低。Nigerloxin 的给药可显著降低糖尿病大鼠晶状体中的脂质过氧化物和 AGEs 水平。Nigerloxin 处理可对抗晶状体中醛糖还原酶和山梨醇脱氢酶活性的增加。Nigerloxin 治疗的糖尿病大鼠晶状体中谷胱甘肽和抗氧化酶的活性显著升高。对治疗大鼠眼睛的检查表明,Nigerloxin 可延缓糖尿病大鼠白内障的发生。结果表明,Nigerloxin 在糖尿病动物中可拮抗多元醇途径酶并增强抗氧化防御系统,暗示其在改善糖尿病性白内障方面的潜力。